The mutant KRAS maintains the GTP-bound active state and overcomes the GTPase activity and initiates nearly 80 different downstream effector signaling pathways including MAPK and PI3K-mTOR signaling which further activates JUN and MYC transcription factors and promotes the cancer cell survival and proliferation (11–15). This evidence concerns the gene KRAS and cancer.